| abstract |
The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide- 1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R. |